Sanofi and Regeneron’s Libtayo successful in lung cancer study

Sanofi (NASDAQ:SNY) and collaboration partner Regeneron Pharmaceuticals (NASDAQ:REGN) announce positive results from a Phase 3 clinical trial comparing Libtayo (cemiplimab) to platinum doublet chemo in patients locally advanced/metastatic non-small cell lung cancer (NSCLC) that tested positive for PD-L1 in ≥50% of tumor cells in a first-line setting.

Treatment with Libtayo decreased the risk of death by 32.4% (hazard ratio = 0.676) compared to chemo.

No new safety signals were observed.

Marketing applications in the U.S. and Europe are next up.

https://seekingalpha.com/news/3564552-sanofi-and-regenerons-libtayo-successful-in-lung-cancer-study